SCHEMBL22987233

SCHEMBL22987233

O=C(O)CCc1ccc(C(=O)NCc2ccccc2OC(F)(F)F)cc1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 8/20 0.69
PPARG P37231 6/20 0.69
PPARD Q03181 1/20 0.56
PPARA Q07869 1/20 0.56
FFAR1 O14842 2/20 0.54
NR1H4 Q96RI1 1/20 0.53
HTT P42858 1/20 0.50
RORC P51449 1/20 0.50
ROCK2 O75116 2/20 0.49
ROCK1 Q13464 1/20 0.49
HDAC1 Q13547 2/20 0.48
RXRA P19793 1/20 0.48
RXRB P28702 1/20 0.48
RXRG P48443 1/20 0.48
FFAR4 Q5NUL3 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13947519 0.82 EPHX2 (0.66) EPHX2PPARGHTTROCK2ROCK1
SCHEMBL28647893 0.81 PPARG (1.00) EPHX2PPARGPPARDPPARA
SCHEMBL28643158 0.81 EPHX2 (0.66) EPHX2PPARGPPARAHTTROCK2
SCHEMBL22987222 0.81 EPHX2 (0.69) EPHX2PPARGPPARDPPARAFFAR1
SCHEMBL28646196 0.80 PPARG (0.60) EPHX2PPARGNR1H4HTTROCK2
SCHEMBL1508357 0.78 FFAR1 (0.56) PPARGFFAR1RORCHDAC1RXRA
SCHEMBL30055829 0.78 FFAR1 (0.56) PPARGFFAR1RORCHDAC1RXRA
SCHEMBL22987232 0.78 EPHX2 (0.67) EPHX2PPARGPPARDPPARAFFAR1
SCHEMBL28654120 0.78 SMN1; SMN2 (0.68) EPHX2PPARGFFAR1NR1H4
SCHEMBL22987225 0.77 PPARG (0.81) EPHX2PPARGFFAR1NR1H4ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238125-A1 Diabetes and Metabolic Syndrome Treatment with a Novel Dual Modulator of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2021-08-05 US disclosed
US-10927069-B2 Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2021-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10927069-B2 Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors EPHX1, EPHX2, PPARG EPHX2 2/4885PPARG 3/4885PPARD 9/4885
US-20210238125-A1 Diabetes and Metabolic Syndrome Treatment with a Novel Dual Modulator of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors EPHX1, EPHX2, PPARG EPHX2 2/4885PPARG 3/4885PPARD 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.